|
|
MultiCell is a
leading-edge biopharmaceutical company committed to the development and
commercialization of breakthrough therapeutics based on a portfolio of new
drug candidates and patented drug development technology platforms.
MultiCell leverages patented methods of modulating the human immune system
to treat serious autoimmune diseases, including multiple sclerosis and
type-1 diabetes, as well as influenza and other health threats.
Currently, the market for therapies addressing such conditions is estimated
at $8 billion worldwide.
The Company’s novel technologies include expertise in Toll-like receptors
and T-cell targeting to modulate both the
innate and adaptive immune systems, enabling the creation of advanced drug
candidates that stimulate or suppress the immune system via
disease-specific targeting of the immune system.
|
|
Wed,
Dec 26
2007 5:14 PM
|
|
MultiCell Technologies To
Increase Focus on Therapeutic Candidates
|
|
Wed,
Oct 10
2007 10:23 AM
|
|
MultiCell Technologies
Signs Worldwide Exclusive License Agreement With Corning Incorporated
|
|
Thu,
July 19
2007 8:00 AM
|
|
MultiCell Technologies
and Fusion Capital Terminate Common Stock Purchase Agreement
|
|
Thu,
May 03
2007 9:00 AM
|
|
MultiCell Technologies
Receives Two International Trademark Protections
|
|
Tue,
Apr 24
2007 8:00 AM
|
|
MultiCell Signs License
Agreement With Eisai Japan to Use Fa2N-4 Cell Line for Drug
Discovery/ADMETOX Applications
|
|
Wed,
Apr 18
2007 9:00 AM
|
|
MultiCell Technologies
Signs Key Formulation and Supply Agreement With Merck KGaA & Co.
Spittal/Drau
|
|
Mon,
Apr 9
2007 9:30 AM
|
|
MultiCell Technologies
Signs Key Supply Agreement With Lundbeck Pharmaceuticals Italy S.p.A.
|
|
Wed,
Mar 21
2007 10:38 AM
|
|
MultiCell Technologies
Announces a New Class of Patented Therapeutics
|
|
Tue,
Mar 6
2007 7:28 PM
|
|
MultiCell Technologies
Completes Private Financing Agreement with La Jolla Cove Investors for
up to $13 Million to Support Development of Advanced Therapeutics
|
|
Thu,
Feb 15
2007 3:30 AM
|
|
MultiCell Technologies
Announces Prospective Cancer Treatment Drug
|
|
Tue,
Feb 6
2007 3:30 AM
|
|
MultiCell Technologies
Announces Progress for MCT-125's Anticipated Phase IIb Clinical Trial
|
|
Thu,
Jan 11
2007 6:30 AM
|
|
MultiCell Technologies'
Proprietary Breakthrough Anti-Cancer Therapy Shown to Prevent
Recurrence of Cancer
|
|
Fri,
Dec 15
2006 6:30 AM
|
|
MultiCell Technologies
Fulfills Upfront License Fee Payment Obligation to Amarin Neuroscience
for MCT-125
|
|
Wed,
Dec 6
2006 5:04 PM
|
|
MultiCell Technologies
Discusses Recent Cancer Treatment Breakthrough and Growing Intellectual
Property Portfolio with CEOcast.com Investor Information Service
|
|
Wed,
Nov 29
2006 6:30 AM
|
|
MultiCell Technologies
Obtains Patent Protection in Several European Countries for Treatment
of Autoimmune Diseases
|
|
Mon,
Nov 27
2006 4:01 PM
|
|
MultiCell Technologies
Releases CEO Letter to Shareholders
|
|
Wed,
Nov 22
2006 6:30 AM
|
|
WebAlert: MultiCell
Technologies Presenting during SmallCapInsights.com's ''Emerging Growth
Forum'' Starting Today at 12 Noon ET
|
|
Tue,
Nov 21
2006 9:25 AM
|
|
Multicell Technologies
Demonstrates Drug Candidate's Powerful Tumor-Destroying Capabilities
for Virally Induced Cancers such as Cervical Cancer
|
|
Mon,
Nov 20
2006 10:06 AM
|
|
MultiCell Technologies
and SmallCapInsights.com Highlight CEOs Presenting at Wednesday's
Anticipated ``Emerging Growth Forum''
|
|
Mon,
Nov 20
2006 9:25 AM
|
|
MultiCell Technologies to
Seek Advanced Human Clinical Trials for Lead Therapeutics Program
|
|
Thu,
Nov 16
2006 4:03 PM
|
|
MultiCell Technologies
Announces SmallCapInsights.com to Host ''Emerging Growth Forum''
Webcast Highlighting Auriga Laboratories, MultiCell Technologies, Peace
Arch Entertainment and Titan Global Holdings
|
|
Tue,
Nov 7
2006 4:01 PM
|
|
MultiCell Technologies
CEO to Present Key Research Data at New York Academy of Sciences'
Animal Models Conference
|
|
Wed,
Nov 01
2006 4:32 PM
|
|
MultiCell Technologies
Posts Journal Article on Research Leading to Company's Recent Patent
Application on Novel Cancer Treatment
|
|
Tue,
Oct 31
2006 11:23 AM
|
|
MultiCell Technologies
Releases Transcript of Recent Investor Conference Call Discussing
Recent Growth Initiatives and Growth of IP Portfolio
|
|
Thu,
Oct 26
2006 11:43 AM
|
|
MultiCell Technologies
Recaps New Investor Conference Call Discussing Recent Drug Development
Initiatives and Strengthened IP Portfolio
|
|
Wed,
Oct 25
2006 06:30 AM
|
|
WebAlert: MultiCell
Technologies Investor Conference Call Starts Today at 12 Noon ET
|
|
Thu,
Oct 12
2006 4:03 PM
|
|
MultiCell Technologies
Announces Milestone Patent Issued by European Patent Office on
Treatments for Autoimmune Diseases
|
|
Wed,
Oct 11
2006 4:02 PM
|
|
WebAlert: MultiCell
Technologies to Release CEO Interview to Discuss Progress in Business
and Drug Development Programs
|
|
Wed,
Oct 11
2006 6:00 PM
|
|
MultiCell Outlines
Portfolio of Next-Generation Immune Modulation Therapeutics Technology
in Updated Investor Fact Sheet
|
|
Fri,
Oct 6
2006 4:01 PM
|
|
MultiCell Announces
?ntellectual Property Portfolio of First-in-Class Technologies Crosses
Threshold of 50 Issued or Pending Patents
|
|
Thu,
Oct 5
2006 6:22 PM
|
|
MultiCell and Fusion
Capital Amend and Restate Common Stock Purchase Agreement to Provide
for $8 Million of Equity Funding
|
|
Thu,
Oct 5
2006 6:00 PM
|
|
MultiCell Technologies
Announces Strategic Initiatives for 2006 and 2007; Company to Focus on Advance
of First-in-Class Immune-based Drug Candidates into Advanced Phase
Human Clinical Trials
|
|
Tue,
Oct 3
2006 3:03 PM
|
|
SmallCapInsights.com
Investment Newsletter Commences Editorial Coverage of MultiCell
Technologies Following Recently Filed Patent on Cancer Treatment
|
[more news...]
|
|
